Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now OTC Markets OTCPK - Delayed Quote • USD Strainsforpains, Inc. (EBYH) Follow Add holdings 0.1630 0.0000 (0.00%) At close: April 25 at 4:00:00 PM EDT Comparisons Indicators Technicals Corporate Events Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for EBYH 1D 5D 1M 3M 6M YTD 1Y 5Y All Date Range 1 min Recent News: EBYH View More All News Press Releases SEC Filings Strainsforpains, Inc. Sets the Stage for Massive Growth in the Cannabis Industry and AI Innovation EBYH Broadcasts Media Kit for the Inaugural 1-Million Strong Killing Cancers, Fight Club, VIP Fundraiser Event, Pre-Sales for Event Sponsorships and VIP Tickets, Final Venue Choice and Inaugural Event Date Forthcoming with Great Appreciation From Cancer Patients Worldwide Strainsforpains EBYH (OTC: EBYH), Collaborates with Mt. Sinai Hospital in New York City and Johns Hopkins in Baltimore to Merge Advanced AI Data Integrations and Interactions Into Its Proprietary Healthcare APP for Instant Multiple Indications and Critical Ailments Professional Analytics Strainsforpains (OTC: EBYH) Formally Announces Alliance with the 1-Million Strong Killing Cancers, Fight Club (1MSFC) and the Inaugural Live 1MSFC #1 MMA Fight for 4th Quarter 2024 in Florida! Appoints Former WWE, TV Executive VP, Mr. Steven A. Smith Jr., as COO of 1-Million Strong Killing Cancers, Fight Club Strainsforpains-EBYH, CEO Simon Shainberg Signs Strategic Product Commercialization Agreement with Cannabis Science; Shainberg’s 2024 Guidance Projects Strong Revenue Growth For Its Multiplied Cannabinoid Drug Commercialization Pipeline